SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) - Get Report today announced it will present at the Stifel Virtual Healthcare Conference on Wednesday November 18, 2020 at 4:00 p.m. ET.
About Evofem BiosciencesEvofem Biosciences, Inc., (EVFM) - Get Report is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate) , is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, ' EVOGUARD ,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com .
Phexxi™ is a trademark of Evofem Biosciences, Inc.
Investor Relations Contact Amy RaskopfEvofem Biosciences, Inc. email@example.com Mobile: (917) 673-5775
Media Contact Ellen ThomasEvofem Biosciences, Inc. firstname.lastname@example.orgMobile: (718) 490-3248
View original content to download multimedia: http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-stifel-virtual-healthcare-conference-301171760.html
SOURCE Evofem Biosciences, Inc.